FGF21 analogues and GLP-1 receptor agonists (GLP-1RAs) exhibit pleiotropic effects across multiple organs; the former improves systemic metabolic regulation and insulin sensitivity (125), while the latter engages the gut-brain-liver axis to control appetite, glycemia, and directly ameliorate hepatic steatosis and inflammation (126). The gene discussed is INS; the disease is Hepatic steatosis.